Travere Therapeutics is a biopharmaceutical company focused on rare diseases, particularly serious kidney and metabolic disorders. Its commercial and late-stage portfolio has centered on treatments such as sparsentan (FILSPARI) for IgA nephropathy and other therapies aimed at underserved rare conditions. The company targets specialist physicians and patients in niche indications where few approved options exist.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 114.5 | — | -12.8 | — |
| Q3 2025 | 164.9 | — | 25.7 | — |
| Q4 2025 | 129.7 | — | 2.7 | — |
| Q1 2026 | 127.2 | — | -37.1 | — |
| Q2 2026 | 169.6 | 48.2% | -34.8 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: VSE Corporation (VSEC), NorthWestern Energy Group, Inc. (NWE), TFS Financial Corporation (TFSL), Garrett Motion Inc. (GTX), Mercury Systems, Inc. (MRCY), The Baldwin Insurance Group, Inc. (BWIN)